First Results of DLBCL patients treated with CAR-T CELLS and enrolled in DESCAR-T registry, A french REAL-LIFE DATABASE for CAR-T CELLS in hematologic malignancies.

CART-T:Retrospective study of the impact of the level of exposure to Fludarabine during lymphodepletion on the efficacy and tolerance of Axicabtagene ciloleucel in the treatment of large cell B-lymphomas

CART-T:TARMAC: Efficacy and safety of CAR-T cells in mantle cell lymphomas with central nervous system involvement

CAR-T:Impact of Radiotherapy on the response of patients treated with CART cells.

CAR-T:Clinical outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma experiencing CAR-T cells therapy failure-

Comparing the Efficacy of CAR-T Cells to Standard of Care in Refractory and Relapsed Large B-cell Lymphomas

Projects in multiple myeloma

PANACEA: Prognostic impact of Proton Pump Inhibitors on response to CAR T-cells

Efficacy and safety of CAR-T in T cell/histiocyte-rich large B-cell lymphoma patients

BMS – Profile of patients in Intent-to-Treat with CAR T-cells, and Efficacy and Safety in relapsed or refractory Large B-Cell Lymphomas

Infectious complications following CAR T-Cells injection

CARTAGE : CAR T-cells in patients aged 75 years and older with diffuse large B cell lymphoma

Study of macrophage activation syndrome associated CAR T-cells in patients with lymphoma and ALL

HGBL – Tolerance and Efficacy of CAR-T in high-grade B-cell lymphoma

TRANSCAR : Comparison of the efficacy and safety of CAR-T in “de novo” DLBCL VS transformed indolent lymphoma (tNHL)

DLBCL – First results of CAR T-cell therapy in patients diagnosed with large B cell lymphoma

DLBCL L2 – 1rst results of axi-cel in 2nd-line of treatement for Large B-Cell Lymphoma

LF – First results of axi-cel and tisa-cel in patients with follicular lymphoma

ETCETERA: Efficacy and safety of CAR-T cells in non-Hodgkin lymphomas with central nervous system involvement

T-cell malignancies after CAR T-cell therapy

DLBCL – Impact of Bridging therapies in Patients with Diffuse Large B-cell Lymphoma After 3 or More Lines of Treatment

DLBCL-3L- Analysis of the DLBCL cohort after 3 or more lines of treatment: outcome of patients according to their response

Sociology and public health thesis: The cell, the industry and the hospital; the healthcare system and the CAR-T promise

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Efficacy and safety of CAR-T cells in immunocompromised patients

LAL – Persistence of B aplasia following CAR T-cells in cute lymphocytic leukemia: impact on the incidence and nature of relapses

Relapses post CAR-T-cell treatment in mantle cell lymphoma

PLWH – People Living With HIV treated by CAR-T in R/R aggressive B-cell lymphomas

CAREFUL: Prognostic impact of intesive care admission for organ suppleance following CAR T-cells

Abbvie – Profile of patients in Intent-to-Treat with CAR T-cells, and Efficacy and Safety in Large B-Cell Lymphomas

Comparative control arm of Phase II clinical trial BICAR with the DESCAR-T registry

Efficacy and safety of CAR-T in the treatment of primary mediastinal lymphoma

Analysis of fungal infections after CAR-T

Use of Siltuximab in the treatment of Cytokine Release Syndromes

Miltenyi – CAR-T efficacy and safety in diffuse large B-cell lymphoma

CARLATE: Outcome of patients relapsing more than 3 months after CAR T-Cell therapy

Treating Richter Syndrome with CAR-T